Formulating guidelines for chemotherapy in advanced breast cancer

William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


More than 180,000 women in the United States will develop breast cancer in 1999. Although the number of breast cancer survivors has risen dramatically due to increased early detection and more effective adjuvant therapy, metastatic breast cancer remains incurable. In recent years, a great deal of emphasis has been placed on the development of combination chemotherapy regimens for the treatment of metastatic disease. More recently, the paradigm may be shifting toward sequential single-agent chemotherapy instead. Clinicians have the challenging task of determining the best sequence of systemic therapy for their patients with metastatic breast cancer. In addition, clinicians and patients together must address the issue of diminishing benefit with continued chemotherapy, ie, when to make the transition to palliative care. In this article, the rationale for a stepwise algorithm for treating metastatic disease will be considered.

Original languageEnglish (US)
Pages (from-to)231-235
Number of pages5
Issue number11 A
StatePublished - Dec 1 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Formulating guidelines for chemotherapy in advanced breast cancer'. Together they form a unique fingerprint.

Cite this